Five poster presentations were authored and presented by Q2
Solutions | EA Genomics colleagues at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Conference in Washington, D.C., in November 2018.
Download the following posters to explore the methods, results, and conclusions for each study.
- Robust TMB values derived from tumor-only material, co-authored by Natalie Mola and Victor Weigman, describes the development and performance of our newly launched bioinformatics tool for the assessment of Tumor Mutational Burden from tumor-only specimens, without a germline control.
- A pan-cancer view of the immune landscape in the tumor microenvironment via RNA and their potential for biomarkers in clinical trials, authored by Wendell Jones, reports on the development of immune cell activity signatures that explain variations in patient outcomes (progression free survival and overall survival) in over 20 tumor indications.
- Validated next generation sequencing assay for the characterization of the T-cell repertoire from RNA, authored by Jennifer Sims, describes our recently launched T-cell receptor sequencing assay. With the sensitivity of 5.7 *10^-6, accuracy of 100%, and the ability to detect TCR RNA fragments both in FFPE specimens and blood, the assay is suitable for the analysis of T-cell-mediated immune response during cancer evolution and treatment, as well as for monitoring minimal residual disease in T-cell malignancies.
- Validated next generation sequencing RNA-based assay of the IGHV mutation status and repertoire diversity, authored by Jeran Stratford, reports on the development of a sequencing assay for the analysis of somatic hypermutations (SHM) in the rearranged immunoglobulin heavy-chain variable (IGHV) gene. A strong prognostic biomarker in Chronic Lymphocytic Leukemia, SHM status of the IGHV gene is commonly exploited as a potential biomarker of drug response in clinical trials of CLL. This Q2 Solutions | EA Genomics IGHV assay remains the only assay in the US certified by the European Research Initiative on CLL (ERIC).
- Classification of the human gut microbiome using a validated 16S rRNA next generation sequencing method, authored by Janet Doolittle-Hall and Scott Yourstone, reports on the 16S rRNA targeted sequencing assay for the analysis of the microbiome in different tissue types including stool and tumor FFPE specimens. Emerging evidence suggest that gut microbiome has a profound impact on the activity of the immune system. Manipulating the bacterial composition of the gut may improve the effects of cancer therapies, and our assay can assist in accurate and sensitive monitoring of constituent and therapeutic microbial species during therapeutic manipulations.